MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on invariant natural killer T (iNKT) cell therapies, announced it will release its third quarter 2024 financial results before market opens on November 14, 2024. The company will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update. The event will be accessible via phone and webcast through the company's investor relations website.
MiNK Therapeutics (NASDAQ: INKT), un'azienda biofarmaceutica in fase clinica specializzata in terapie con cellule T natural killer invarianti (iNKT), ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura del mercato il 14 novembre 2024. L'azienda organizzerà una telesegreteria e una webcast alle 8:30 ora dell'Est per discutere i risultati e fornire un aggiornamento aziendale. L'evento sarà accessibile tramite telefono e webcast attraverso il sito web delle relazioni con gli investitori dell'azienda.
MiNK Therapeutics (NASDAQ: INKT), una empresa biofarmacéutica en etapa clínica centrada en terapias con células T natural killer invariantes (iNKT), anunció que publicará sus resultados financieros del tercer trimestre de 2024 antes de la apertura del mercado el 14 de noviembre de 2024. La empresa llevará a cabo una conferencia telefónica y una transmisión web a las 8:30 a.m. ET para discutir los resultados y proporcionar una actualización corporativa. El evento será accesible por teléfono y transmisión web a través del sitio web de relaciones con inversionistas de la empresa.
MiNK Therapeutics (NASDAQ: INKT), 임상 단계의 생명공학 회사로 불변 자연 살해 T 세포(iNKT) 치료법에 중점을 두고 있으며, 2024년 11월 14일 시장 개장 전에 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 이 회사는 오전 8:30(동부 표준시) 에 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다. 이 이벤트는 회사의 투자자 관계 웹사이트를 통해 전화와 웹캐스트로 접근할 수 있습니다.
MiNK Therapeutics (NASDAQ: INKT), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies par cellules T natural killer invariantes (iNKT), a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 avant l'ouverture des marchés le 14 novembre 2024. L'entreprise organisera une conférence téléphonique et un webinaire à 8h30 ET pour discuter des résultats et fournir une mise à jour de l'entreprise. L'événement sera accessible par téléphone et par webinaire via le site web des relations investisseurs de l'entreprise.
MiNK Therapeutics (NASDAQ: INKT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf therapeutische Ansätze mit invariant natürlichen Killer-T-Zellen (iNKT) konzentriert, gab bekannt, dass es seine Finanzergebnisse für das dritte Quartal 2024 vor Markteröffnung am 14. November 2024 veröffentlichen wird. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Die Veranstaltung wird telefonisch und über den Webcast über die Investor-Relations-Website des Unternehmens zugänglich sein.
- None.
- None.
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 5606166
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/ukmiq8bo/.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
When will MiNK Therapeutics (INKT) release Q3 2024 earnings?
How can I access MiNK Therapeutics (INKT) Q3 2024 earnings call?
What time is MiNK Therapeutics (INKT) Q3 2024 earnings call?
